Fawzi Abu Rous: Recent Innovative FDA Approvals in Lung Cancer
Fawzi Abu Rous, Thoracic Medical Oncologist at the Henry Ford Health, shared a post on LinkedIn:
“In recent months, the U.S. Food and Drug Administration (FDA) has approved effective and innovative treatments for lung cancer patients:
Zongertinib: For patients with HER2 mutations after immunotherapy and chemotherapy failure
Sunvozertinib: For patients with EGFR exon 20 insertion mutations after chemotherapy failure
Datopotamab deruxtecan: For patients with EGFR mutations after previous treatments have failed
Telisotuzumab vedotin: for lung tumors with elevated levels of c-MET protein after failure of previous treatments
These targeted therapies represent a paradigm shift in the treatment of lung cancer… However, their usefulness is limited in our region if the use of genetic testing for lung tumors is not universalized, especially for stage 4 patients.
In recent months, the FDA has granted accelerated approval for several innovative lung cancer treatments:
Zongertinib: for HER2-mutant NSCLC after progression on chemo-immunotherapy
Sunvozertinib: for EGFR exon 20 insertion mutations after progression on chemotherapy
Datopotamab deruxtecan: for EGFR-mutant NSCLC after progression on prior therapies
Telisotuzumab vedotin: for patients with high c-MET expression after progression on prior therapies
These therapies represent meaningful advances – but access to biomarker testing must expand in order to see the benefits of these drugs.”
More posts featuring Fawzi Abu Rous.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023